ArticleFrontiers in medicine2026
Rapid-onset respiratory failure caused by diabetic ketoacidosis complicated with pulmonary mucormycosis: a case report and literature review.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the rapid progression and key treatment strategies for invasive pulmonary mucormycosis caused by Rhizopus in patients with diabetic ketoacidosis (DKA). Methods: We report a fatal case of severe Rhizopus pneumonia in a patient with DKA and conducted a systematic review of relevant cases from PubMed and Web of Science for descriptive analysis. Results: A 39-year-old male with DKA developed severe lung lesions within days post-admission. Despite confirmation via pathological diagnosis and the initiation of liposomal amphotericin B therapy, the patient succumbed rapidly. Incorporating 15 cases identified from the literature, the total cohort comprised 16 patients, yielding an overall mortality rate of 25% (4/16). Cases involving DKA frequently exhibited narrow diagnostic windows and rapid progression to respiratory failure. Most cases (11/15) received amphotericin B-based therapy, and some with localized lesions (7/15) underwent surgical resection. Conclusion: Pulmonary mucormycosis with DKA can progress rapidly and carries high risk. Treatment typically involves amphotericin B preparations, supplemented by surgery for focal disease. Key strategies include maintaining a high index of clinical suspicion in high-risk hosts, early pathological/molecular diagnosis, prompt antifungal therapy alongside metabolic correction, and timely surgical evaluation for localized lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.